Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02651688
Other study ID # ZA-205
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 11, 2016
Est. completion date May 2, 2017

Study information

Verified date June 2019
Source Repros Therapeutics Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism [confirmed morning testosterone (T) ≤300 ng/dL] following a 6 month diet and 15 month exercise program.


Description:

To compare the effects of 12 months of treatment with enclomiphene 12.5 mg, 25 mg, or placebo capsules on body composition and metabolic parameters in overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T≤300 ng/dL) following a 6 month diet and 15 month exercise program. Participants must not have been treated with testosterone products in the 6 months prior to the study and must not ever have used testosterone products for a year or longer.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date May 2, 2017
Est. primary completion date May 2, 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Overweight (Body Mass Index (BMI) 30 to 42 (kg/m^2) inclusive) males age 18 to 60 inclusive.

- Waist circumference = 40 inches (101.6 cm).

- Previously or concurrently diagnosed as having secondary hypogonadism.

- Must have 2 morning testosterone assessments at Visit 1, collected before 10 AM, 2-4 days apart, and both of which must be = 300 (ng/dL).

- Luteinizing hormone (LH) >1.4 and < 9.4 milli International units per milliliter (mIU/mL) (at Visit 1 only).

- Glycated hemoglobin A1c (HbA1c) =7.5.

- Stable weight for last 3 months (+/- 10 pounds).

- Participant lives or works within 10 miles of the gym that will be used for the study.

- Must be fit enough to participate in the fitness program.

- Ability to complete the study in compliance with the protocol requirements.

- Ability to understand and provide written informed consent.

Exclusion Criteria:

- Any use of testosterone products (injectable, pelleted, transdermal or sublingual) in the 6 months prior to the study or any prior use of testosterone products for 12 months or longer at any time.

- Use of testosterone, Clomid, 5a-reductase inhibitors, human chorionic gonadotropin (hCG), androgen, estrogen, anabolic steroid, dehydroepiandrosterone (DHEA), or herbal hormone products during the study.

- Use of Clomid in the past year.

- Known hypersensitivity to Clomid.

- Allergy to soy, peanuts or latex.

- Chronic use of glucocorticoids (chronic use of inhaled or topical glucocorticoids is acceptable).

- History of drug abuse or chronic narcotic use including methadone.

- A recent history of alcoholism or illegal substance or steroid abuse (<2 years) or presence of moderate alcohol use (>21 drinks per week).

- Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.

- A hematocrit >54%.

- Presence or known history of hyperprolactinemia with or without a tumor (prolactin >20 ng/mL).

- Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a prostate specific antigen (PSA)>3.6.

- Current or history of breast cancer.

- Uncontrolled hypertension based on the Investigator's assessment at screening.

- History of bulimia nervosa or binge eating.

- Participant has (had) a lap band or undergone gastric bypass surgery.

- Participant has celiac disease or gluten intolerance.

- Participant has Type I diabetes.

- Participant has any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study.

- Enrolled and randomized (if applicable) in a previous enclomiphene study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
One matching placebo capsule daily in the morning with approximately 8 ounces of water for up to 12 months.
Enclomiphene
Enclomiphene capsule daily in the morning with approximately 8 ounces of water for up to 12 months.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Repros Therapeutics Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in Lean Body Mass (LBM) at Week 48 LBM was assessed using dual-energy X-ray absorptiometry (DXA). A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Body Strength (Chest Press Weight) at Week 48 Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Body Strength (Leg Press Weight) at Week 48 Body strength was assessed from maximum chest and leg press weight achieved, using an inclined plane leg press and vertical chest press. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Luteinizing Hormone (LH) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter LH measured in milli-International Units per milliliter (mIU/mL). A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Testosterone (T) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter T. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Dihydrotestosterone (DHT) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter DHT. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Estradiol (E2) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the hormone parameter E2. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Ratio of Testosterone: Estradiol (T:E2) at Week 48 The T:E2 ratio was calculated as the value of T/value of E2 using the same units. A positive change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Ratio of Dihydrotestosterone: Testosterone (DHT:T) at Week 48 The DHT:T ratio was calculated as the value of DHT/value of T using the same units. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter HbA1c. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Glucose Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter Glucose. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood C-reactive Protein (CRP) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter CRP. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Interleukin-6 (IL-6) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter IL-6. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Tumor Necrosis Factor Alpha (TNF-a) Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter TNF-a . A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Leptin Level at Week 48 A blood sample was collected at Baseline and Week 48 for the assessment of the metabolic parameter leptin. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Homeostatic Model of Assessment - Insulin Resistance (HOMA-IR) at Week 48 The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (µU/mL) × fasting plasma glucose (mmol/L)/22.5. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Blood Quantose-Insulin Resistance (IR) Score at Week 48 Quantose-IR is a laboratory-developed test that assesses insulin resistance. Quantose-IR score is based on a linear regression algorithm utilizing the quantitative measures (natural log transformed) of alpha-hydroxybutyrate, oleate, linoleoylglycerophosphocholine and insulin and was designed to estimate the natural log of insulin-induced glucose infusion rate normalized by whole body mass. The algorithm score is converted to the Quantose-IR score within a range of 1-120 by an arithmetic calculation where higher scores denote greater insulin resistance. A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Body Mass Index (BMI) at Week 48 BMI is calculated as weight (kg)/height(cm^2). A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Waist Circumference at Week 48 A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
Primary Change From Baseline in Weight at Week 48 A negative change from Baseline indicates improvement. Baseline (Day 0) to Week 48
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2